Standout Papers

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-p... 2011 2026 2016 2021 635
  1. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance) (2014)
    William M. Sikov, Donald A. Berry et al. Journal of Clinical Oncology
  2. IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease (2011)
    Alessandra Geremia, Carolina V. Arancibia-Cárcamo et al. The Journal of Experimental Medicine

Immediate Impact

36 by Nobel laureates 9 from Science/Nature 112 standout
Sub-graph 1 of 18

Citing Papers

A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
2021 StandoutScienceNobel
Breast cancer
2021 Standout
7 intermediate papers

Works of Baljit Singh being referenced

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
2014 Standout
IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease
2011 Standout

Author Peers

Author Last Decade Papers Cites
Baljit Singh 1390 895 1027 948 46 3.9k
Gloria H. Su 2357 821 1295 896 91 5.8k
Göran Hallmans 1437 802 857 611 74 6.7k
Elizabeth M. Ward 1933 925 1300 350 41 5.9k
Paige M. Bracci 1656 636 742 423 128 4.2k
J F Fraumeni 1623 2819 718 1025 48 6.9k
Arne Bakka 1574 808 166 666 80 3.7k
Sara H. Olson 2413 564 504 1507 79 4.5k
Shih-Jen Hwang 1030 528 458 498 27 4.2k
Irene Visintin 927 824 850 3125 43 6.3k
Per Lenner 2459 531 1357 504 149 6.5k

All Works

Loading papers...

Rankless by CCL
2026